ReviewVascular health and risk management2008
Carvedilol in hypertension treatment.
Review in Vascular health and risk management, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 93 citations in OpenAlex.
- Characteristics and long-term follow-up of participants with peripheral arterial disease during ALLHAT.Journal of general internal medicine · 2014Trial
- Role of antioxidant property of carvedilol in mild to moderate hypertensive patients: A prospective open-label study.Indian journal of pharmacologyTrial
- Risk assessment based on spectrophotometric signals used in eco-friendly analytical scenarios for estimation of carvedilol and hydrochlorothiazide in pharmaceutical formulation.Scientific reports · 2024Article
- Lipid Horizons: Recent Advances and Future Prospects in LBDDS for Oral Administration of Antihypertensive Agents.International journal of hypertension · 2024Review
- Population Pharmacokinetic-Pharmacodynamic Modeling of Carvedilol to Evaluate the Effect of Cytochrome P450 2D6 Genotype on the Heart Rate Reduction.Journal of Korean medical science · 2023Article
- Gi-protein-coupled βActa biochimica et biophysica Sinica · 2022Review
- Preparation and Characterization of a Novel Mucoadhesive Carvedilol Nanosponge: A Promising Platform for Buccal Anti-Hypertensive Delivery.Gels (Basel, Switzerland) · 2022Article
- Pharmacist-Led Medication Evaluation Considering Pharmacogenomics and Drug-Induced Phenoconversion in the Treatment of Multiple Comorbidities: A Case Report.Medicina (Kaunas, Lithuania) · 2021Article
- Development of an Age-Appropriate Mini Orally Disintegrating Carvedilol Tablet with Paediatric Biopharmaceutical Considerations.Pharmaceutics · 2021Article
- Formulation and Characterization of Acetazolamide/Carvedilol Niosomal Gel for Glaucoma Treatment: In Vitro, and In Vivo Study.Pharmaceutics · 2021Article
- Site-Selective Aerobic C-H Monoacylation of Carbazoles Using Palladium Catalysis.The Journal of organic chemistry · 2021Article
- Molecular and Cellular Mechanisms of Electronegative Lipoproteins in Cardiovascular Diseases.Biomedicines · 2020Review
- Octopamine signaling in the metazoan pathogenDisease models & mechanisms · 2018Article
- Clinical trial experience with CA4P anticancer therapy: focus on efficacy, cardiovascular adverse events, and hypertension management.Gynecologic oncology research and practice · 2018Review
- Late-Stage Diversification of Biologically Active Molecules via Chemoenzymatic C-H Functionalization.ACS catalysis · 2016Article
- Directed evolution of RebH for site-selective halogenation of large biologically active molecules.Angewandte Chemie (International ed. in English) · 2015Article
- Development and optimization of carvedilol orodispersible tablets: enhancement of pharmacokinetic parameters in rabbits.Drug design, development and therapy · 2015Article
- Novel treatment approaches in hypertensive type 2 diabetic patients.World journal of diabetes · 2014Review
- Taking diabetes to heart--deregulation of myocardial lipid metabolism in diabetic cardiomyopathy.Journal of the American Heart Association · 2013Review
- Synthesis of conjugated chitosan and its effect on drug permeation from transdermal patches.Indian journal of pharmaceutical sciences · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although beta-blockers have been previously shown to effectively reduce blood pressure (BP) and have been used for hypertension treatment for over 40 years, their effect on cardiovascular morbidity and mortality in hypertensive patients remains controversial and its use in uncomplicated hypertension is currently under debate. However, data on the above field derive mainly from studies which were conducted with older agents, such as atenolol and metoprolol, while considerable pharamacokinetic and pharmacodynamic heterogeneity is present within the class of beta-blockers. Carvedilol, a vasodilating non-cardioselective beta-blocker, is a compound that seems to give the opportunity to the clinician to use a cardioprotective agent without the concerning hemodynamic and metabolic actions of traditional beta-blocker therapy. In contrast with conventional beta-blockers, carvedilol maintains cardiac output, has a less extended effect on heart rate and reduces BP by decreasing vascular resistance. Further, several studies has shown that carvedilol has a beneficial or at least neutral effect on metabolic parameters, such as glycemic control, insulin sensitivity, and lipid metabolism, suggesting that they could be used in subjects with the metabolic syndrome or diabetes without negative consequences. This article summarizes the distinct pharmacologic, hemodynamic, and metabolic properties of carvedilol in relation to conventional beta-blockers, attempting to examine the potential use of this agent for hypertension treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.